

Sedation for Less Invasive Surfactant Administration in preterm infants: A Systematic Review and Meta-analysis

Laura Moschino¹, Viraraghavan Vadakkencherry Ramaswamy², Irwin Karl Marcel Reiss³, Eugenio Baraldi¹, Charles Christoph Roehr^{*4,5,6}, Sinno Henricus Paulus Simons³

Affiliations:

¹ Neonatal Intensive Care Unit, Department of Women's and Children's Health, Padova University Hospital, Italy

² Department of Neonatology, Ankura Hospital, Hyderabad, India

³ Department of Pediatrics, Division of Neonatology, Erasmus University Medical Center – Sophia Children's Hospital, Rotterdam, the Netherlands

⁴ Newborn Services, Southmead Hospital, North Bristol Trust, Bristol, United Kingdom

⁵ University of Bristol, Faculty of Health Sciences, Bristol, United Kingdom

⁶ National Perinatal Epidemiology Unit, Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

Corresponding author: Professor Charles C. Roehr, National Perinatal Epidemiology Unit, Nuffield Department of Population Health, Medical Sciences, Division, University of Oxford, Oxford, United Kingdom; Email: charles.roehr@npeu.ox.ac.uk ; Phone: +44 1865 289750

Category of study: Systematic Review

Impact

- The effect of sedative drugs (analgesics, sedatives, anesthetics) compared to the effect of no-sedation for LISA in preterm infants with RDS is underexplored.
- This systematic review and meta-analysis assesses the impact of sedative drugs compared to no-sedation for LISA on short-term pulmonary outcomes and potential adverse events.
- Sedative drugs for LISA temporarily affect the newborn's breathing (desaturation, apnea) and increase the need for nasal intermittent positive pressure ventilation,. For most outcomes, Certainty of Evidence is low/very low.

ABSTRACT

Background

Sedation to preterm neonates receiving Less Invasive Surfactant Administration (LISA) for respiratory distress syndrome (RDS) is controversial.

Methods

Systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies (OS) to evaluate the effect of sedative drugs for LISA on respiratory outcomes and adverse effects.

Results

One RCT (78 neonates) and two OS (519 neonates) were analyzed in pair-wise meta-analysis and 30 studies (2164 neonates) in proportion-based meta-analysis. Sedative drugs might not affect the duration of procedure [RCT: MD (95% CI); -11 (-90 - 67) seconds; OS: Mean difference (MD) 95%CI: -60 (-178-58) seconds; Low certainty of evidence (CoE)]. Evidence for success at first attempt and rescue intubation was uncertain (very low CoE). The risk of nasal intermittent positive pressure ventilation [RCT: 1.97 (1.38-2.81); OS: RR, 95% CI: 2.96 (1.46-6.00), low CoE], desaturation [RCT: RR, 95% CI: 1.30 (1.03-1.65), low CoE], and apnea [OS: RR, 95% CI: 3.13 (1.35-7.24), very low CoE] might be increased with sedation. Bradycardia, hypotension and mechanical ventilation were comparable between groups (low CoE).

Conclusions

Use of sedative drugs for LISA temporarily affects the newborn's breathing. Further trials are warranted to explore the use of sedation for LISA.

INTRODUCTION

One of the most pressing calls in the care of preterm neonates is that for an effective yet minimally invasive approach to surfactant administration. Exogenous surfactant replacement and non-invasive respiratory support (NRS) have become the most successful treatments for preterm infants with respiratory distress syndrome (RDS)¹. The combination of NRS and surfactant replacement was first described in 1992². Today, less invasive surfactant administration (LISA) encompasses the delivery of surfactant to spontaneously breathing infants with RDS for whom the application of continuous positive airway pressure (CPAP) alone does not suffice³. Acknowledging the increasing evidence of its effectiveness, the current European Consensus Guidelines on RDS management recommend LISA as the preferred mode for targeted surfactant delivery in spontaneously breathing babies with RDS⁴. LISA has proven to be safe in extremely preterm infants of less than 28 gestational age (GA)^{5,6}. The recent Cochrane Review⁷, together with other systematic reviews and meta-analyses^{3,8-12}, concludes that LISA effectively reduces the risk of death or bronchopulmonary dysplasia (BPD), the need for invasive mechanical ventilation (IMV) in the first 72 hours and the incidence of major complications compared to surfactant administration through an endotracheal tube (ETT), or continuation of NRS without surfactant administration or surfactant administration followed by continuing IMV. The recently concluded OPTIMIST trial has confirmed the benefit of the procedure in reducing the incidence of BPD at 36 weeks postmenstrual age in extremely preterm infants¹³.

However, despite gaining increasing popularity in the last years¹⁴⁻¹⁶, several aspects of the LISA procedure remain unresolved, like the choice of device to deliver surfactant^{17,18}, the target population¹⁹⁻²¹, and most importantly, the insufficient knowledge around the routine use of sedative drugs^{22,23}.

The objective of this systematic review and meta-analysis is to evaluate the effect of sedation during LISA when compared to non-pharmacological standard measures in preterm neonates of less than 37 weeks gestational age (GA) with RDS.

METHODOLOGY

This systematic review and meta-analysis was conducted in accordance with PRISMA guidance²⁴ and MOOSE Checklist²⁵. The protocol for this systematic review was registered with PROSPERO (CRD42021278954).

Literature search

A systematic database search (PubMed, Embase, Medline Ovid and Cochrane Central) from inception through October 2021 was performed. The search terms used included: “surfactant” OR “poractant” OR “curosurf” OR “lung surfactant”, AND “minimally invasive procedure” OR “catheter” OR “feeding tube” OR “less invasive surfactant administration” OR “noninvasive” OR “non-invasive” OR “lisa” OR “mist”, AND “low-birth-weight” OR “low-birth weight” OR “preterm” OR “premature” OR “infant” OR “newborn”. Additional articles were identified by a manual search of the cited references. The Literature search strategy is provided in the online Supplementary Material.

Inclusion criteria

Titles were screened for relevance and duplications. Studies were selected if they focused on human preterm neonates (<28 days of life, born <37 GA) with RDS and need for surfactant according to the criteria of the study. Randomized controlled trials (RCTs) and quasi-randomized controlled trials (qRCT) evaluating surfactant administration via tracheal catheter with or without the use of sedative drugs (including analgesics, sedatives, anesthetics, and any type of drug to improve comfort) were selected for comparison of outcomes. LISA/Minimally Invasive Surfactant Therapy (MIST) procedure could be performed with flexible or semi-rigid catheter, with or without Magill’s forceps, with or without the use of videolaryngoscopy. Studies whose original aim was to compare LISA/MIST versus surfactant administration via INSURE/endotracheal intubation or versus

conventional treatment (intubation and surfactant with delayed extubation or only non-invasive ventilation) were included as well. Observational studies with a prospective or retrospective designs were also eligible for inclusion. Letters to Editors/Commentaries, case series, unpublished studies (e.g., conference abstracts) and animal studies were excluded. In addition, studies including populations of mixed age groups were excluded unless they provided sub-group data for neonates under 28 days of age and born less than 37 weeks GA, or those resident within the neonatal unit. Abstracts for which full texts were unavailable and those published in non-English literature were excluded. In the case of included abstract but full text unavailable authors' were contacted directly by the reviewers.

Outcomes

The primary outcomes were success at first attempt of trachea catheterization, the need for early intubation (rescue intubation during the procedure or within 2 hours from LISA), and the duration of LISA procedure (in seconds). Secondary outcomes included the need for nasal intermittent positive pressure ventilation (nIPPV) during the procedure, rate of IMV in the first 24 and 72 hours, and the incidence of side effects (oxygen desaturation, bradycardia, apnea, hypotension).

Data extraction and synthesis

Two authors independently extracted data in pairs. In case of any conflicts, a third reviewer was consulted. RCTs and observational studies with an intervention and comparator arm were synthesized in a pairwise meta-analysis. A random effects model was used to pool the data. Mantel Haenszel method was used for the synthesis of dichotomous outcomes and an inverse variance method was utilized for pooling of continuous outcomes. Heterogeneity was evaluated with Cochran Q, I^2 and τ^2 values. The effect estimates were depicted in forest plots as risk ratio (RR) with 95% confidence interval (95% CI). For the proportion-based meta-analysis of observational studies and single arms of RCTs, raw data, logit transformed data or Freeman-Tukey double arcsine

transformation was used as appropriate. Inverse variance method was utilized to pool the data in proportion-based meta-analysis. R-software (R Foundation for Statistical Computing, Vienna, Austria) was used for data analysis.

Risk of bias (RoB) and Certainty of evidence (CoE)

Risk of bias (RoB) was performed using RoB version 2.0 for the RCT²⁶ and Risk Of Bias In Non-randomized Studies-of Intervention (ROBINS-I)²⁷ for non-randomized studies with an intervention and comparator arm. RoB was not ascertained for studies included in the proportion based meta-analysis. Certainty of evidence (CoE) was evaluated based on the GRADE working group recommendation²⁸. CoE assessment was not feasible for the effect estimates of proportion-based meta-analysis.

RESULTS

A total of 670 studies were assessed for full text extraction after the removal of 294 duplicates. Of the full texts evaluated, 637 were excluded due to valid reasons and 33 studies were included in the final synthesis (**Table 1**). **Figure 1** shows the PRISMA flow diagram. One RCT²⁹ and two observational studies^{30,31} with an intervention and comparator arm were analyzed in a pairwise meta-analysis. Nineteen single arms of RCTs^{5,6,32-34,37,40-42,44,45,47-53,56} and 11 observational studies^{16,17,20,35,36,38,39,43,46,54,55} were analyzed in a proportion-based meta-analysis for the various outcomes. One study was available only as protocol and abstract at the time of the analysis, therefore it was not included¹³. The characteristics of the included studies are given in **Table 1**.

Pair-wise meta-analysis

Primary outcomes

Meta-analysis of observational studies^{30,31} indicated that the chance of successful endotracheal catheterization at the first attempt was similar in LISA with sedatives compared to LISA without sedatives [RR 95% CI: 0.94 (0.87; 1.02); CoE: Very low] (**Figure 2**).

The analysis of the RCT²⁹ and the pooled estimate from the observational studies^{30,31} did not reveal any statistically significant difference in early intubation when LISA was performed with or without sedatives [RCT: RR 95% CI: 0.21 (0.03; 1.83); CoE: Very low; OS: RR 95% CI: 2.52 (0.50; 12.79); CoE: Very low] (**Figure 3A and 3B**).

Time to completion of the procedure did not show any statistically significant difference between the sedation and the no-sedation groups, as evaluated in the RCT²⁹ [Mean difference (MD) (95% CI): -11 (-90 to 67) seconds; CoE: Low] and in the observational study³⁰ [MD 95% CI: -60 (-178; 58) seconds; CoE: Very low] (**Figure 4A and 4B**).

Secondary outcomes

Pooled estimates from two observational studies^{30,31} indicated that the risk of apnea might be statistically higher in the LISA sedation group when compared to the no-sedation group [RR 95% CI: 3.13 (1.35; 7.24); CoE: Very low] (**Figure 5A**).

The requirement of nIPPV during LISA procedure was higher in LISA with sedatives when compared to LISA without sedatives [RCT²⁹: RR 95% CI: 1.97 (1.38; 2.81); CoE: Low; OS³¹: RR 95% CI: 2.96 (1.46; 6.00); CoE: Very low] (**Figure 5B and 5C**).

The RCT²⁹ and the pooled results from observational studies^{30,31} did not shown an increased risk of bradycardia [RCT: RR 95% CI: 1.50 (0.55; 4.06); CoE: Low; OS: RR 95% CI: 0.57 (0.24; 1.36); CoE: Very low] when sedation was used with LISA when compared to no sedation.

For the outcome desaturation, whilst there was increased risk in the LISA sedation group when compared to the no-sedation group in the RCT²⁹ [RR 95% CI: 1.30 (1.03; 1.65); CoE: Low], similar findings were not evident from the observational study³¹ [RR 95% CI: 1.35 (0.92; 1.97); CoE: Very low].

The risk of hypotension was similar during LISA with and without sedatives [RCT²⁹: RR 95% CI: 2.55 (0.62; 10.46); CoE: Low; OS³⁰: RR 95% CI: 1.18 (0.24; 5.87); CoE: Very low] These outcomes are summarized in **Figure 6**.

There was no difference in the risk of IMV within 24 hours in the LISA sedation group when compared to the no-sedation group [RCT²⁹: RR 95% CI: 1.43 (0.58; 3.55); CoE: Low; OS^{30,31}: RR 95% CI: 1.48 (0.94; 2.33); CoE: Very low] (**Supplemental Figure S1**).

For the outcome need for IMV within 72 hours only proportion-based meta-analysis could be performed.

Proportion-based meta-analysis

Proportion-based meta-analysis of single arms of RCTs^{5,6,33,37,40-42,45,46,48,49,53,56} and observational studies^{17,20,30,31,38,55} showed no statistically significant differences between LISA conducted with sedation and without sedation for the primary outcome successful endotracheal catheterization at first attempt. Pooled estimate indicated that 86% (80%-90%) of the neonates who were instituted LISA had successful tracheal catheterization at first attempt (**Supplemental Figure S2**).

The need for early intubation did not differ between LISA with sedatives and LISA without sedatives from the proportion-based meta-analysis of studies^{29-31,35,36,39,41,46,47,51}. Seven percent (3%-11%) of the neonates instituted LISA with or without sedation required early intubation (**Supplemental Figure S3**).

Time to completion of the procedure did not show any statistically significant difference between the sedation and the no-sedation groups^{20,29,30,35,36,42} (**Supplemental Figure S4**).

There were no sub-group differences between LISA with sedation (ketamine, propofol, fentanyl, multiple drugs analyzed together, and rescue sedation) and LISA without sedation for the outcome IMV within 72 hours. The overall rate of IMV requirement within 72 hours in the whole LISA group was 25% (19%-31%)^{5,6,16,17,20,31-37,39-41,43-49,51-55} (**Supplemental Figure S5**).

RoB and CoE assessment

The only RCT²⁹ included in this systematic review and for the pair-wise meta-analysis had ‘some concerns’ for the domain ‘deviation from intended intervention’ as some randomized neonates were subsequently excluded from the analysis. Further, the domain of ‘missing outcome data’ was assessed as having a high risk as unequal number of participants’ data were missing from the final analysis and the reasons for this were not the same between the groups. It is likely that missingness depended on the true value. Hence, an overall high risk of bias was adjudged for this RCT. The observational studies^{30,31} were scored as having serious risks of bias as there was serious risk of confounding for one study and serious risk of confounding, selection and selective reporting for the other study. The RoB table is given in **Supplementary Table S1**.

CoE for most of the outcomes from the RCT and observational studies was very low to low. The summary of findings table and the reasons for downgrading the level of evidence are given in **Tables 2 and 3**.

DISCUSSION

The use of sedative drugs to improve the quality of the procedure and to decrease the distress of the newborn during LISA is an important topic of debate where currently no consensus has been achieved. The American Academy of Pediatrics⁵⁷ and groups of European neonatologists⁵⁸ recommend that for non-emergency intubations, premedication including analgesia and sedatives should be used. Similarly, the 2019 RDS European Consensus Guidelines consider “good practice to avoid discomfort during elective intubation by using a sedative or analgesic”⁵⁴. A summary of the most used sedative and analgesic drugs in neonatology with their properties and potential side effects is given in **Supplementary Table S2**.

LISA implies the insertion of a laryngoscope and possibly the use of a Magill forceps. Both these actions are considered painful and distressing⁵⁹, and can be complicated by adverse events like apnoea, bradycardia⁶⁰, chest-wall rigidity and crying. Consequences may also include failed

attempts at tracheal catheterization and a potential increase of the intracranial pressure with impaired cerebral venous return and risk for intraventricular haemorrhage^{61,62}. Nevertheless, the thin catheter delivery of surfactant relies on the baby's spontaneous breathing on CPAP to enhance surfactant distribution, which might be easily depressed by the use of sedative drugs⁶³, increasing the risk of apnoea and the need for rescue intubation during the procedure. For this latter reason, infants treated with LISA receive about 30% less analgesics and/or sedatives than infants receiving surfactant via ETT⁶⁴, and most surveys conducted so far show that around 50% of neonatologists perform the first LISA attempt without sedation^{14,64-71} (**Supplementary Table S3**). However, the opinion of many authors is that sedation performed by expert neonatologists with pharmacological knowledge should be used to ensure patients' comfort and reduce the risk of acute responses induced by awake laryngoscopy^{63,72}.

Proper use of sedative drugs for LISA should reduce discomfort while maintaining good balance between sedation and self-ventilation. Drug properties should ideally include a rapid onset, a very short duration of action, and no suppression of spontaneous breathing with an overall short- and long-term safety profile. From a developmental pharmacological perspective, it seems almost impossible to find the suitable drug to sedate preterm neonates adequately for a short period of time. The premature infant's body composition, that contains about 90% of water, warrants relatively higher doses to reach an adequate plasma level for most water-soluble drugs, whereas drug clearance is known to be extremely low over the first day of life, because of low urinary excretion and low activity of drug metabolizing enzymes. Consequently, safe short-acting drugs may act as long-lasting medicines with side effects.

In most studies using sedative drugs for LISA, either low dose propofol^{29,30,39} or a combination of atropine and ketamine was administered³⁵. Interestingly, promising sedative drugs capable of maintaining spontaneous breathing with less risk of respiratory depression, like dexmedetomidine, are still underexplored for this purpose.

The results of our meta-analysis indicate with low CoE that sedation for LISA might not affect the duration of the procedure, when compared to LISA without sedation. However, this outcome may be influenced by the experience of the proceduralists, who were highly variable among the included studies ranging from expert neonatologists to pediatric residents. In the study by de Kort et al.³⁸, in fact, the success rate was significantly correlated with quality of technical conditions and experience of the performer. In our review, the CoE was very low for the other primary outcomes of success at first attempt of catheterization of the trachea and requirement of early intubation, thus precluding any reasonable conclusions.

The results of our meta-analysis also show that LISA performed with sedative drugs may provoke an increased risk for desaturation and requirement for nIPPV during the procedure, with the CoE being low. The risk of apnea was also higher in the LISA sedation group, but the CoE was very low. Hence, the evidence for this outcome is also uncertain. Whether the use of caffeine as a pre-medication along with the routinely utilized drug atropine^{35,38,47,48,51} prior to LISA procedure would reduce many of these short-term adverse events needs to be evaluated in future trials.

Other adverse short-term and medium-term outcomes which might be considered severe, such as bradycardia, hypotension and need for mechanical ventilation, were similar in the LISA sedation group when compared to the no-sedation group, as evaluated in our meta-analysis.

The RCT²⁹ and one of the two observational studies³⁰ with the intervention and comparator arms included in our review indicate that low dose propofol (1 mg/kg) may reduce the COMFORTneo score compared to “awake” administration of surfactant during LISA. However, this benefit was obtained at expenses of major risks of desaturation and need for nIPPV in both studies.

It should be considered that the highly variable pharmacokinetics and -dynamics among preterm neonates, especially in the first days of life, may affect the response to sedatives and explain why in some cases, despite their use, the infants may not receive sufficient comfort³⁵. It is probable that procedural sedation and analgesia for these infants should be based on an individualized, tailored approach rather than a standardized one²³.

Our review and meta-analysis highlight the uncertainty of evidence for many of the outcomes due to paucity of studies on the use of sedation for LISA. Further dose finding trials and adequately powered multi-center RCTs comparing LISA with and without sedative drugs with robust study designs are warranted. These trials should explore the effect of no sedation versus the use of sedatives, anesthetics or analgesics and evaluate possible effect modifiers of these drugs, such as gestational age, different dosages, timing of caffeine administration and use of atropine. Minimization might be an appropriate strategy to evaluate these in large multi-center trials. Further, the personnel involved in the trials needs to have comparable expertise in the LISA procedure. Finally, the trials should be adequately powered to assess long-term neurodevelopmental outcomes including motor and cognitive functions.

At the time of writing, one systematic review on the topic was published with similar findings on most of the included outcomes (eight studies, 945 infants)⁷³, and there were four ongoing trials on use of sedation for LISA, of which one compares propofol versus placebo^{74,75}, one the use of ketamine vs fentanyl⁷⁶, one ketamine vs placebo⁷⁷, and one fentanyl along with atropine versus placebo⁷⁸. Two currently recruiting Italian studies aim to assess stress during surfactant administration by cortisol concentration in preterm infants receiving or not remifentanyl for LISA or INSURE⁷⁹, or fentanyl for LISA⁸⁰. These studies will provide further precious information on the best sedation strategy for non-invasive surfactant administration.

Our review has its limitations. Due to paucity of studies evaluating this PICOST, we performed proportion-based meta-analyses for some of the outcomes with an aim to study indirect comparisons. However, there are no clear recommendations for CoE assessment of results derived from such analysis, which lacks control groups and can only provide the estimate of the proportion of events with the intervention. Further, this review predisposes for selective reporting bias. Finally, there was significant heterogeneity between studies on the type of non-pharmacological measures instituted in the control arm.

CONCLUSION

The use of sedative drugs for LISA in preterm neonates with RDS might be associated with an increased risk of desaturation and requirement of nIPPV, without an effect on duration of the procedure, risk of bradycardia, hypotension and requirement of mechanical ventilation. The evidence is very uncertain for most of the other outcomes due to very low CoE. Multi-center RCTs with robust study designs are warranted to compare short and long-term outcomes of LISA when performed with or without sedative drugs. It is probable, however, that procedural sedation and analgesia for preterm infants should be individualized.

Data availability statement

All data generated or analysed during this study are included in this published article [and its supplementary information files].

REFERENCES

1. Hentschel, R., Bohlin, K., van Kaam, A., Fuchs, H., Danhaive, O. Surfactant replacement therapy: from biological basis to current clinical practice. *Pediatr Res.* **88(2)**, 176-183 (2020).
2. Verder, H., et al. Surfaktantbehandling af nyfødte med respiratorisk distress-syndrom primært behandlet med nasalt kontinuerligt positivt luftvejstryk. En pilotundersøgelse [Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study]. *Ugeskr Laeger.* **154(31)**, 2136–2139 (1992).
3. More, K., Sakhuja, P., & Shah, P. S. Minimally invasive surfactant administration in preterm infants: a meta-narrative review. *JAMA Pediatr.* **168(10)**, 901–908 (2014).
4. Sweet, D.G., et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. *Neonatology.* **115(4)**, 432-450 (2019).
5. Göpel, W., et al.; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. *Lancet.* **378(9803)**, 1627-1634 (2011).
6. Kribs, A., et al.; NINSAPP Trial Investigators. Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial. *JAMA Pediatr.* **169(8)**, 723-730 (2015).
7. Abdel-Latif, M. E., Davis, P. G., Wheeler, K. I., De Paoli, A. G., & Dargaville, P. A. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. *Cochrane Database Syst Rev.* **5(5)**, CD011672 (2021).
8. Aldana-Aguirre, J.C., Pinto, M., Featherstone, R.M., Kumar, M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory

- distress syndrome: a systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed.* **102(1)**,F17-F23 (2017).
9. Rigo, V., Lefebvre, C., Broux, I. Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis. *Eur J Pediatr.* **175(12)**, 1933–1942 (2016).
 10. Lau, C.S.M., Chamberlain, R.S., Sun, S. Less invasive surfactant administration reduces the need for mechanical ventilation in preterm infants: a meta-analysis. *Glob Pediatr Health.* **4**,2333794X17696683 (2017).
 11. Cao, Z.L., et al. Less invasive surfactant administration in preterm infants with respiratory distress syndrome-an updated meta-analysis. *J Chin Med Assoc.* **83(2)**,170-179 (2020).
 12. Bellos, I., Fitrou, G., Panza, R., Pandita, A. Comparative efficacy of methods for surfactant administration: a network meta-analysis. *Arch Dis Child Fetal Neonatal Ed.* **106(5)**, 474-487 (2021).
 13. Dargaville, P.A., et al.; OPTIMIST-A Trial Investigators. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. *JAMA.* **326(24)**, 2478-2487 (2021).
 14. Klotz, D., Porcaro, U., Fleck, T., Fuchs, H. European perspective on less invasive surfactant administration-a survey. *Eur J Pediatr.* **176(2)**, 147-154 (2017).
 15. Herting, E., Härtel, C., Göpel, W. Less invasive surfactant administration: best practices and unanswered questions. *Curr Opin Pediatr.* **32(2)**,228-234 (2020).
 16. Kribs, A., et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. *Klin Padiatr.* **222(1)**,13-17 (2010).
 17. Kribs, A., Pillekamp, F., Hünseler, C., Vierzig, A., Roth, B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age ≤ 27 weeks). *Paediatr Anaesth.* **17(4)**,364-369 (2007).

18. Dargaville, P. A., Aiyappan, A., Cornelius, A., Williams, C., De Paoli, A. G. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. *Arch Dis Child Fetal Neonatal Ed.* **96**,F243–F248 (2011).
19. Dargaville, P.A., Ali, S.K., Jackson, H.D., Williams, C., De Paoli, A.G. Impact of minimally invasive surfactant therapy in preterm infants at 29-32 weeks gestation. *Neonatology.* **113(1)**, 7–14 (2018).
20. Dargaville, P.A., et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. *Arch Dis Child Fetal Neonatal Ed.* **98(2)**:F122-6 (2013).
21. Vento, M., Bohlin, K., Herting, E., Roehr, C.C., Dargaville, P.A. Surfactant Administration via Thin Catheter: A Practical Guide. *Neonatology.* **116(3)**,211-226 (2019).
22. Balakrishnan, A., Sanghera, R.S., Boyle, E.M. New techniques, new challenges—The dilemma of pain management for less invasive surfactant administration? *Paediatr Neonatal Pain [Review]*. **3(1)**, 2-8 (2021).
23. Peterson, J., den Boer, M.C., Roehr, C.C. To Sedate or Not to Sedate for Less Invasive Surfactant Administration: An Ethical Approach. *Neonatology.* 1-8 (2021).
24. Page, M.J., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *J Clin Epidemiol.* **134**,178-189 (2021).
25. Stroup, D.F., et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. *JAMA.* **283(15)**, 2008–2012 (2000).
26. *Cochrane Handbook for Systematic Reviews of Interventions* Chapter 8.
<https://methods.cochrane.org/risk-bias-2>. Accessed November 30, 2021.
27. *Cochrane Handbook for Systematic Reviews of Interventions* Chapter 25.
<https://methods.cochrane.org/methods-cochrane/robins-i-tool>. Accessed November 30, 2021.
28. Santesso, N., et al; GRADE Working Group. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol.* **119**, 126-135 (2020).

29. Dekker, J., et al. Sedation during minimal invasive surfactant therapy: A randomised controlled trial. *Arch Dis Child Fetal Neonatal Ed.* **104(4)**, F378-F383 (2019).
30. Dekker, J., et al. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. *Neonatology.* **109(4)**, 308-313 (2016).
31. Krajewski, P., Szpecht, D., Hożejowski, R. Premedication practices for less invasive surfactant administration - results from a nationwide cohort study. *J Matern Fetal Neonatal Med.* **25**, 1-5 (2020).
32. Akcay, N., et al. Comparison of LISA vs INSURE technique using nasal intermittent positive pressure ventilation (NIPPV) support In preterm infants: a randomized controlled trial. *Med J Bakirkoy.* **17(1)**, 1-6 (2021).
33. Bao, Y., Zhang, G., Wu, M., Ma, L., Zhu, J. A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center. *BMC Pediatr.* **15**, 21 (2015).
34. Boskabadi, H., Maamouri, G., Gharaei Jomeh, R., Zakerihamidi, M. Comparative study of the effect of the administration of surfactant through a thin endotracheal catheter into trachea during spontaneous breathing with intubation (intubationsurfactant-extubation method). *J Clin Neonatol.* **8(4)**, 227-231 (2019).
35. Bourgoin, L., et al. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. *Acta Paediatr Int J Paediat.* **107(7)**, 1184-1190 (2018).
36. Brotelande, C., et al. Premedication with ketamine or propofol for less invasive surfactant administration (LISA): observational study in the delivery room. *Eur J Pediatr.* (2021). doi: 10.1007/s00431-021-04103-1.
37. Choupani, R., Mashayekhy, G., Hmidi, M., Kheiri, S., Khalili Dehkordi, M. A comparative study of the efficacy of surfactant administration through a thin intratracheal catheter and its administration via an endotracheal tube in neonatal respiratory distress syndrome. *Iran J Neonatol.* **9(4)**, 33-40 (2018).

38. de Kort, E., et al. Quality assessment and response to less invasive surfactant administration (LISA) without sedation. *Pediatr Res.* **87(1)**, 125-30 (2020).
39. Descamps, C.S., et al. Propofol for sedation during less invasive surfactant administration in preterm infants. *Arch Dis Child Fetal Neonatal Ed [Letter]*. **102(5)**, F455 (2017).
40. Gupta, B.K., Saha, A.K., Mukherjee, S., Saha, B. Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial. *Eur J Pediatr.* **179(8)**, 1287-1293 (2020).
41. Halim, A., Shirazi, H., Riaz, S., Gul, S.S., Ali, W. Less Invasive Surfactant Administration in Preterm Infants with Respiratory Distress Syndrome. *J Coll Physicians Surg Pak.* **29(3)**, 226-330 (2019).
42. Han, T., et al. Minimally Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter Randomized Study in China. *Front Pediatr.* **8**, 182 (2020).
43. Höck, M., Posod, A., Waltner-Romen, M., Kiechl-Kohlendorfer, U., Griesmaier, E. Less invasive surfactant administration is associated with a higher need for nonpharmacological pain-relieving interventions compared to the intubation-surfactant extubation technique in preterm infants. *Paediatr Neonatal Pain.* **3(1)**, 29-35 (2021).
44. Jena, S.R., et al., On Behalf Of Sure Group. Surfactant therapy in premature babies: SurE or InSurE. *Pediatr Pulmonol.* **54(11)**, 1747-1752 (2019).
45. Kanmaz, H.G., Erdeve, O., Canpolat, F.E., Mutlu, B., Dilmen, U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. *Pediatrics.* **131(2)**, e502–e509 (2013).
46. Klebermass-Schrehof, K., et al. Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. *Neonatology.* **103(4)**, 252-8 (2013).

47. Mirnia, K., et al. Comparison outcome of surfactant administration via tracheal catheterization during spontaneous breathing with INSURE. *Med J Islamic World Acad Sci.* **21(4)**, 143-148 (2013).
48. Mohammadizadeh, M., Ardestani, A.G., Sadeghnia, A.R. Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome: Feasibility and outcome. *J Res Pharm Pract.* **4(1)**, 31-36 (2015).
49. Mosayebi, Z., et al. A randomized trial comparing surfactant administration using InSurE technique and the minimally invasive surfactant therapy in preterm infants (28 to 34 weeks of gestation) with respiratory distress syndrome. *Journal of J Compr Pediatr.* **8(4)**, e60724 (2017).
50. Okur, N., et al. Neonatal pain and heart rate variability in preterm infants treated with surfactant: a pilot study. *Arch Argent Pediatr.* **117(6)**, 397 (2019).
51. Olivier, F., et al. Efficacy of minimally invasive surfactant therapy in moderate and late preterm infants: A multicentre randomized control trial. *Paediatr Child Health.* **22(3)**, 120-124 (2017).
52. Pareek, P., et al. Less Invasive Surfactant Administration (LISA) vs. Intubation Surfactant Extubation (InSurE) in Preterm Infants with Respiratory Distress Syndrome: A Pilot Randomized Controlled Trial. *J Trop Pediatr.* **67(4)**:fmab086 (2021).
53. Sabzehei, M.K., Basiri, B., Shokouhi, M., Ghremani, S., Moradi, A. Comparison of minimally invasive surfactant therapy with intubation surfactant administration and extubation for treating preterm infants with respiratory distress syndrome: a randomized clinical trial. *Clin Exp Pediatr.* doi: 10.3345/cep.2021.00297 (2021).
54. Shetty, S., et al. Less Invasive Surfactant Administration in Very Prematurely Born Infants. *AJP Rep.* **11(3)**:e119-e122 (2021).
55. Tinoco Mendoza, G., Allgood, C., Tan, A. Minimally invasive surfactant therapy for moderate to late premature neonates with respiratory distress syndrome born in a non-tertiary unit. *J Paediatr Child Health.* **57(10)**:1658-1661 (2021).

56. Yang, G., et al. Effects of less invasive surfactant administration (LISA) via a gastric tube on the treatment of respiratory distress syndrome in premature infants aged 32 to 36 weeks. *Medicine (Baltimore)*. **99(9)**, e19216 (2020).
57. Kumar, P., Denson, S.E., Mancuso, T.J. Premedication for nonemergency endotracheal intubation in the neonate. *Pediatrics*. **125**, 608–615 (2010).
58. Ancora, G., et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. *Acta Paediatr*. **108**, 208–217 (2019).
59. Wycoff, C.C. Endotracheal intubation: effects on blood pressure and pulse rate. *Anesthesiology*. **21**, 153–158 (1960).
60. Marshall, T.A., Deeder, R., Pai, S., Berkowitz, P., Austin, T.L. Physiologic changes associated with endotracheal intubation in preterm infants. *Crit Care Med*. **12**, 501–503 (1984).
61. Friesen, R.H., Honda, A.T., Thieme, R.E. Changes in anterior fontanel pressure in preterm neonates during tracheal intubation. *Anesth Analg*. **66**, 874–878 (1987).
62. Oei, J., Hari, R., Butha, T., Lui, K. Facilitation of neonatal nasotracheal intubation with premedication: A randomized controlled trial. *J Paediatr Child Health*. **38**, 146–150 (2002).
63. De Luca, D., et al. Less invasive surfactant administration: a word of caution. *Lancet Child Adolesc Health*. **4(4)**, 331–340 (2020).
64. Mehler, K., et al.; German Neonatal Network (GNN). Use of analgesic and sedative drugs in VLBW infants in German NICUs from 2003 to 2010. *Eur J Pediatr*. **172(12)**, 1633–1639 (2013).
65. Jeffreys, E., Hunt, K., Dassios, T., Greenough, A. UK survey of less invasive surfactant administration. *Arch Dis Child Fetal Neonatal Ed*. **104(5)**, F567 (2019).
66. Heiring, C., Jonsson, B., Andersson, S., Björklund, L.J. Survey shows large differences between the Nordic countries in the use of less invasive surfactant administration. *Acta Paediatr*. **106(3)**, 382–386 (2017).

67. Fernandez, C., Boix, H., Camba, F., Comuñas, J.J., Castillo, F. Less Invasive Surfactant Administration in Spain: A Survey Regarding Its Practice, the Target Population, and Premedication Use. *Am J Perinatol.* **37(3)**, 277-280 (2020).
68. Szczapa, T., Hożejowski, R., Krajewski, P.; Study Group. Implementation of less invasive surfactant administration in clinical practice-Experience of a mid-sized country. *PLoS One.* **15(7)**, e0235363 (2020).
69. Öncel, M.Y., Erdevi, Ö. A national survey on use of less invasive surfactant administration in Turkey. *Turk J Pediatr.* **62(5)**, 787-794 (2020).
70. Bhayat, S., Kaur, A., Premadeva, I., Reynolds, P., Gowda, H. Survey of less Invasive Surfactant Administration in England, slow adoption and variable practice. *Acta Paediatr.* **109(3)**, 505-510 (2020).
71. Kurepa, D., Perveen, S., Lipener, Y., Kakkilaya, V. The use of less invasive surfactant administration (LISA) in the United States with review of the literature. *J Perinatol.* **39(3)**, 426-432 (2019).
72. Reynolds, P., et al. Less-Invasive Surfactant Administration for Neonatal Respiratory Distress Syndrome: A Consensus Guideline. *Neonatology.* **118(5)**:586-592 (2021).
73. Tribolet, S., Hennuy, N., Snyers, D., Lefèbvre, C., Rigo, V. Analgosedation before Less-Invasive Surfactant Administration: A Systematic Review. *Neonatology.* 1-14 (2022).
74. NCT04016246. Chevallier, M., Durrmeyer, X., Ego, A., Debillon, T., the PROLISA Study Group. Propofol versus placebo (with rescue with ketamine) before less invasive surfactant administration: study protocol for a multicenter, double-blind, placebo controlled trial (PROLISA). *BMC Pediatrics.* **20(100)**, 1-9 (2020).
75. EUCTR2018-002876-41-FR . Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-002876-41-FR> 2018.

76. Nct. Premedication for Less Invasive Surfactant Administration.
<https://clinicaltrials.gov/show/NCT03735563>. 2018.
77. Nct. The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST) (LISA KGS). <https://clinicaltrials.gov/ct2/show/NCT04409665>. 2020.
78. Premedication for Less Invasive Surfactant Administration Study (PRELISA). NCT05065424
<https://clinicaltrials.gov/show/NCT05065424>, 2021 | added to CENTRAL: 31 October 2021 |
2021 Issue 10.
79. Nct. Stress Assessment With and Without Analgesia During Surfactant Therapy in Preterm Infants. <https://clinicaltrials.gov/show/NCT04073173>. 2019.
80. Nct. Study on the Effects of Different Premedication for LISA on Stress and Cerebral Tissue Oxygenation in Preterm Infants. <https://clinicaltrials.gov/show/nct03718507>. 2018.

Funding/Support: No funding was secured for this study.

Competing Interests: The authors have no conflicts of interest relevant to this article to disclose.

Consent Statement: No consent was required for this study.

Contributors' Statement:

LM, VVR, CCR and SHPS gave substantial contributions to conception and design, acquisition of data, analysis and interpretation of data of this manuscript.

LM, VVR, IR, EB, CCR, and SHPS drafted the article and revised it critically for important intellectual content.

All the authors approved the final version of the manuscript to be published.

Acknowledgements

This paper was written as part of the European Society for Pediatric Research (ESPR) Young Investigators Mentoring Program 2019. No financial assistance was received in support of this manuscript, although the ESPR financially supported LM and SS for the YIMP Meeting at the Joint of European Neonatal Societies (JENS) 2019. The authors would like to thank Sven Wellman and Heike Rabe for the initiative of this program and the ESPR for their support. The authors wish to thank Wichor Bramer from the Erasmus MC Medical Library for developing and updating the search strategies.

FIGURE LEGEND

Figure 1. PRISMA flow diagram.

Figure 2. Pair-wise meta-analysis for the outcome 'Successful catheterization of trachea at first attempt'.

Figure 3. Figure 3A and 3B: Pair-wise meta-analysis of RCT and of observational studies for the outcome ‘Early intubation during or within 2 hours of LISA’.

Figure 4A and 4B. Forest plots for the outcome ‘Time to completion of the procedure’ from the RCTs and observational studies.

Figure 5. Figure 5A: Pair-wise meta-analysis of observational studies for the outcome ‘Apnea during LISA’; **Figure 5B and 5C:** Pair-wise meta-analysis of RCT and observational studies for the outcome ‘Requirement of nasal intermittent positive pressure ventilation during LISA’.

Figure 6. Pair-wise meta-analysis of RCT and observational studies for the outcomes ‘Bradycardia’, ‘Desaturation’, and ‘Hypotension’.